PL2424529T3 - Nowe postępowania terapeutyczne z zastosowaniem centakwiny - Google Patents
Nowe postępowania terapeutyczne z zastosowaniem centakwinyInfo
- Publication number
- PL2424529T3 PL2424529T3 PL10770318T PL10770318T PL2424529T3 PL 2424529 T3 PL2424529 T3 PL 2424529T3 PL 10770318 T PL10770318 T PL 10770318T PL 10770318 T PL10770318 T PL 10770318T PL 2424529 T3 PL2424529 T3 PL 2424529T3
- Authority
- PL
- Poland
- Prior art keywords
- centhaquin
- therapeutic treatments
- novel therapeutic
- treatments
- novel
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Quinoline Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17425709P | 2009-04-30 | 2009-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2424529T3 true PL2424529T3 (pl) | 2017-06-30 |
Family
ID=43032771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10770318T PL2424529T3 (pl) | 2009-04-30 | 2010-04-29 | Nowe postępowania terapeutyczne z zastosowaniem centakwiny |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20120083447A1 (enExample) |
| EP (1) | EP2424529B1 (enExample) |
| JP (2) | JP5498571B2 (enExample) |
| CN (2) | CN102458399B (enExample) |
| AU (1) | AU2010241564B2 (enExample) |
| BR (1) | BRPI1013903B1 (enExample) |
| CA (1) | CA2759791C (enExample) |
| ES (1) | ES2614813T3 (enExample) |
| PL (1) | PL2424529T3 (enExample) |
| WO (1) | WO2010127096A2 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010127096A2 (en) | 2009-04-30 | 2010-11-04 | Midwestern University | Novel therapeutic treatments using centhaquin |
| PL2890376T3 (pl) * | 2012-08-31 | 2018-05-30 | Pharmazz, Inc. | Sposoby i kompozycje do resuscytacji hipotensyjnej |
| US20170326166A1 (en) * | 2014-10-17 | 2017-11-16 | University Of Virginia Patent Foundation | Compositions and methods for treating pituitary tumors |
| EP4364811A3 (en) * | 2018-05-03 | 2024-07-10 | Midwestern University | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
| US20220362239A1 (en) * | 2021-05-11 | 2022-11-17 | Pharmazz, Inc. | Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in coronavirus disease (covid-19) |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3954987A (en) * | 1972-12-22 | 1976-05-04 | Sandoz, Inc. | 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock |
| DE2421382A1 (de) | 1974-05-03 | 1975-11-20 | Council Scient Ind Res | 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge |
| JPS604186B2 (ja) | 1974-05-13 | 1985-02-01 | カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ | １―ｍ―トリル―４―（Ｂ―２―キノリエチル）―ピペラジンの製造法 |
| US3983121A (en) | 1974-07-01 | 1976-09-28 | Council Of Scientific And Industrial Research | 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof |
| DE2557784C2 (de) * | 1975-12-22 | 1986-04-17 | Hoechst Ag, 6230 Frankfurt | Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate |
| US4761417A (en) * | 1982-05-14 | 1988-08-02 | Maroko Peter R | Compounds, compositions and method of treatments for improving circulatory performance |
| EP0126327A1 (en) | 1983-04-26 | 1984-11-28 | Frank J. Macri | Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same |
| US5055470A (en) | 1989-06-01 | 1991-10-08 | Bristol-Myers Squibb Co. | Method of treatment of ischemia in brain |
| US5922681A (en) | 1992-09-14 | 1999-07-13 | Warner-Lambert Company | Endothelin antagonists |
| US20040063719A1 (en) * | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
| US6545048B1 (en) | 1999-06-29 | 2003-04-08 | California Institute Of Technology | Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity |
| US6113915A (en) | 1999-10-12 | 2000-09-05 | Allergan Sales, Inc. | Methods for treating pain |
| US6369114B1 (en) | 1999-11-30 | 2002-04-09 | Institute Of Critical Care Medicine | Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation |
| GB0013378D0 (en) | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Use of therapeutic benzamide derivatives |
| SE0004455D0 (sv) | 2000-12-01 | 2000-12-01 | Milos Pekny | Method for neuron regeneration in the central nervous system |
| AU2002241736A1 (en) | 2000-12-21 | 2002-07-01 | Bristol-Myers Squibb Company | Method for preventing or treating pain by administering an endothelin antagonist |
| US20030232787A1 (en) | 2001-05-08 | 2003-12-18 | Dooley David James | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic |
| WO2003009805A2 (en) | 2001-07-23 | 2003-02-06 | Brigham And Women's Hospital, Inc. | Analgesic methods using endothelin receptor ligands |
| US7030082B2 (en) | 2001-09-07 | 2006-04-18 | Nobex Corporation | Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith |
| US7973064B2 (en) * | 2001-11-27 | 2011-07-05 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating an opiate analgesic |
| US7351692B2 (en) * | 2002-06-19 | 2008-04-01 | The Board Of Trustees Of The University Of Illinois | Method and composition for potentiating the antipyretic action of a nonopioid analgesic |
| JP2006508086A (ja) | 2002-10-24 | 2006-03-09 | ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ | 固形腫瘍を予防および治療するための方法および組成物 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| CA2506850C (en) | 2002-11-20 | 2014-05-13 | Neuronova Ab | Compounds and methods for increasing neurogenesis |
| US7906140B2 (en) | 2004-06-17 | 2011-03-15 | Virun, Inc. | Compositions for mucosal delivery of agents |
| WO2008043102A2 (en) | 2006-10-06 | 2008-04-10 | Transition Therapeutics Inc. | Vasoactive intestinal polypeptide compositions |
| JP2009506119A (ja) | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
| US9829494B2 (en) | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| JP2009530407A (ja) | 2006-03-23 | 2009-08-27 | アミリン・ファーマシューティカルズ，インコーポレイテッド | 代謝性疾患の治療用のエンドセリン及びエンドセリン受容体アゴニスト |
| US8623823B2 (en) | 2007-08-21 | 2014-01-07 | Midwestern University | Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist |
| US20100189802A1 (en) | 2007-08-21 | 2010-07-29 | Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation | Method for treatment of vascular hyperpermeability |
| CN101374259B (zh) | 2007-08-22 | 2012-08-08 | 华为技术有限公司 | 实现多媒体彩铃和多媒体彩像业务的方法和装置 |
| EP2165706A1 (en) | 2008-09-18 | 2010-03-24 | BioAlliance Pharma | Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers. |
| WO2010127096A2 (en) | 2009-04-30 | 2010-11-04 | Midwestern University | Novel therapeutic treatments using centhaquin |
| US8980874B2 (en) | 2009-04-30 | 2015-03-17 | Midwestern University | Method and composition for treating diabetic ketoacidosis |
| KR101743280B1 (ko) | 2010-06-17 | 2017-06-02 | 얀센 파마슈티카 엔.브이. | Ccr2의 사이클로헥실-아제티디닐 길항제 |
| KR101418941B1 (ko) | 2011-04-04 | 2014-07-15 | 서울대학교병원 | 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물 |
| PL2890376T3 (pl) | 2012-08-31 | 2018-05-30 | Pharmazz, Inc. | Sposoby i kompozycje do resuscytacji hipotensyjnej |
| US10561704B2 (en) | 2013-07-08 | 2020-02-18 | Midwestern University | Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist |
| EP4364811A3 (en) | 2018-05-03 | 2024-07-10 | Midwestern University | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
-
2010
- 2010-04-29 WO PCT/US2010/032942 patent/WO2010127096A2/en not_active Ceased
- 2010-04-29 US US13/266,205 patent/US20120083447A1/en not_active Abandoned
- 2010-04-29 CN CN201080029672.5A patent/CN102458399B/zh active Active
- 2010-04-29 EP EP10770318.3A patent/EP2424529B1/en active Active
- 2010-04-29 BR BRPI1013903-6A patent/BRPI1013903B1/pt active IP Right Grant
- 2010-04-29 PL PL10770318T patent/PL2424529T3/pl unknown
- 2010-04-29 CN CN201410085543.8A patent/CN103989682B/zh active Active
- 2010-04-29 JP JP2012508721A patent/JP5498571B2/ja active Active
- 2010-04-29 ES ES10770318.3T patent/ES2614813T3/es active Active
- 2010-04-29 AU AU2010241564A patent/AU2010241564B2/en active Active
- 2010-04-29 CA CA2759791A patent/CA2759791C/en active Active
-
2014
- 2014-03-07 JP JP2014044799A patent/JP5727642B2/ja active Active
-
2017
- 2017-09-25 US US15/714,008 patent/US10828368B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP5727642B2 (ja) | 2015-06-03 |
| JP2014141502A (ja) | 2014-08-07 |
| WO2010127096A2 (en) | 2010-11-04 |
| CN103989682A (zh) | 2014-08-20 |
| EP2424529A2 (en) | 2012-03-07 |
| JP2012525422A (ja) | 2012-10-22 |
| CN102458399A (zh) | 2012-05-16 |
| US20120083447A1 (en) | 2012-04-05 |
| WO2010127096A3 (en) | 2011-03-24 |
| BRPI1013903B1 (pt) | 2020-03-03 |
| AU2010241564A2 (en) | 2012-10-04 |
| ES2614813T3 (es) | 2017-06-02 |
| CN103989682B (zh) | 2016-03-30 |
| EP2424529B1 (en) | 2016-12-28 |
| EP2424529A4 (en) | 2012-11-28 |
| CA2759791C (en) | 2018-04-10 |
| CN102458399B (zh) | 2014-04-23 |
| JP5498571B2 (ja) | 2014-05-21 |
| AU2010241564A1 (en) | 2011-11-17 |
| US20180085461A1 (en) | 2018-03-29 |
| BRPI1013903A2 (pt) | 2016-07-19 |
| AU2010241564B2 (en) | 2014-07-31 |
| US10828368B2 (en) | 2020-11-10 |
| CA2759791A1 (en) | 2010-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB0908957D0 (en) | Therapeutic agents | |
| GB0916666D0 (en) | Photodynamic therapy device | |
| GB0900599D0 (en) | Treatment | |
| GB0900484D0 (en) | Therapeutic agent | |
| GB201013898D0 (en) | Well treatment | |
| PL2424529T3 (pl) | Nowe postępowania terapeutyczne z zastosowaniem centakwiny | |
| GB0913968D0 (en) | Treatment | |
| GB0916997D0 (en) | Combination therapy | |
| GB201001521D0 (en) | Treatment | |
| GB0907973D0 (en) | Combination therapy | |
| GB0910493D0 (en) | Therapeutic agents | |
| GB0906026D0 (en) | Therapeutic compounds | |
| GB0915802D0 (en) | Therapeutic treatments | |
| GB0816300D0 (en) | Therapeutic treatments | |
| GB0816301D0 (en) | Therapeutic treatments | |
| GB0922098D0 (en) | Therapeutic use | |
| GB0903321D0 (en) | Therapy | |
| GB0921244D0 (en) | Therapy | |
| GB0914820D0 (en) | WATerian therapy | |
| GB0903319D0 (en) | Therapy | |
| GB201014918D0 (en) | Therapeutic treatments | |
| GB201014917D0 (en) | Therapeutic treatments | |
| GB0904261D0 (en) | New therapeutic use | |
| GB0919821D0 (en) | Therapeutic agents | |
| GB0919820D0 (en) | Therapeutic agents |